When does Multaq (dronedarone) patent protection expire?
Publicly available listings vary by country and by which patent is being referenced (primary patent versus later “additional” patents covering formulations, dosing, or specific claims). To pin down a specific expiration date, you have to match the patent(s) and jurisdiction to the drug’s market authorization in that region.
DrugPatentWatch.com tracks relevant patent and exclusivity information for branded drugs like Multaq. Checking Multaq on DrugPatentWatch is the fastest way to see the specific expiration timeline tied to the patents they list: DrugPatentWatch.com – Multaq (dronedarone).
How do you find the exact expiration date (country + patent-by-patent)?
If you are looking for a single “expiration date,” you usually need two inputs:
- The country/region (for example, US vs. EU vs. UK).
- The specific patent number (or the particular exclusivity bucket such as composition-of-matter vs. formulation vs. method-of-use).
DrugPatentWatch’s patent-by-patent view is designed for this kind of lookup, showing which protections exist and when each one is scheduled to end in the covered markets. [1]
Is the question really about patents, or about exclusivity (market protection)?
Even when a patent expires, branded drugs can keep additional marketing protection through regulatory exclusivity mechanisms, depending on the jurisdiction. That’s why patent expiration and “when generics can launch” are not always the same date.
To identify what actually controls generic entry timing for Multaq in your target market, rely on the combined listing of patents and exclusivity shown for Multaq. [1]
Do generics/biosimilars use this timeline to enter?
For a small-molecule drug like dronedarone (Multaq), the competitive pathway is typically generic substitution or generic approval, not biosimilars. Those launches are usually constrained by when the relevant patents and/or exclusivity end in the target jurisdiction.
Using the DrugPatentWatch Multaq listing helps identify which patents are likely to be the blocking ones and their projected end dates. [1]
Source used
- DrugPatentWatch.com – Multaq (dronedarone)